Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.
BACKGROUND It has been shown that many women with polycystic ovary syndrome ( PCOS ) are 25-hydroxyvitamin D ( 25OHD ) insufficient . Both statin treatment and vitamin D supplementation have been shown to improve biochemical hyper and rogenemia , insulin resistance , and markers of inflammation in patients with PCOS , raising the possibility that some of the statin effects are mediated through vitamin D. METHODS We conducted this r and omized , double-blind placebo controlled study to assess the effect of atorvastatin on serum 25OHD concentrations in patients with PCOS . Forty medication-naive patients with PCOS were r and omized to either atorvastatin 20 mg daily or placebo for 3 months . After completing the initial 3 months of atorvastatin or placebo , both groups of patients participated in a 3-month extension study with metformin 1500 mg daily . We measured changes in 25OHD concentrations by use of t and em mass spectrometry . RESULTS Mean ( SD ) baseline 25OHD concentrations were comparable between the 2 groups [ 45.9 ( 2.4 ) vs 44.8 ( 1.8 ) nmol/L ; P = 0.7 ] . There was a significant increase in 25OHD concentrations with atorvastatin [ 45.9 ( 2.4 ) vs 60.8 ( 3.5 ) nmol/L ] compared with placebo [ 44.8 ( 1.8 ) vs 41.8 ( 3.2 ) nmol/L ; P = 0.02 ] . Three-month treatment with metformin maintained the improvement of 25OHD  with atorvastatin compared to baseline [ 45.9 ( 2.4 ) vs 61.8 ( 3.5 ) , P ≤ 0.01 ) . There were no significant changes in 25OHD concentrations in the placebo group after 12 weeks of metformin . CONCLUSIONS Among patients with polycystic ovary syndrome , 12 weeks of atorvastatin led to a clinical ly significant rise in 25OHD concentrations . This may represent a beneficial pleiotropic effect of statins on 25OHD concentrations
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .